

Targeted Solutions for Cellular and Genomic Therapy

At StarLine, the Orion team is committed to identifying cost containment opportunities for high-dollar therapies. Our suite of services range from the tailored support and clinical expertise of our Orion Nurse Navigators to the guidance and proficient service of our top-notch claims department.

FAST FACTS ON CELL & GENE THERAPY

- The US Food & Drug Administration (FDA) is on track to approve 10-20 new cell and gene therapies per year by 2025.
- By 2025, it is estimated that 100,000 patients will receive treatment with a cell or gene therapy with costs for these treatments exceeding more than \$15 billion.
- There are currently 2,000+ clinical trials underway, with approximately 10% of them in phase III, exploring both new cell and gene therapies as well as expanded indications for current FDA-approved therapies.
- To date, the highest cost drug on the market is a gene therapy for the treatment of Hemophilia B, Hemgenix, with an estimated price tag of \$3.5 million.
- There are currently six FDA-approved CAR-T cell therapies on the market: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma and Carvykti. Projected costs for CAR-T cell therapy range between \$500,000-\$600,000 per drug.



OFFERING AN AVERAGE
*Savings of
up to 65%*

ORION'S COMPREHENSIVE PROGRAM INCLUDES

- Facilitate direct contracts for cell & gene therapies
- Leverage preferred pricing from our vendor partners
- Provide clinical consulting on the appropriate use of cell and gene therapies with evidence-based research and review to ensure the execution of best practices
- Offer educational resources related to the clinical pipeline for cell & gene therapies
- Serve as a trusted partner in navigating and managing catastrophic claims

To learn more about Cellular and Genomic therapy and how Orion Navigator may assist your program please contact us at Orion@starlinegroup.com or (508) 809-7475.